Finance Watch: Patient Square Capital Raises Mega-Fund, Topping Out At $3.9bn
Follows Dimension’s New $350m Tech-Focused Life Science Fund
Executive Summary
Private Company Edition: Patient Square’s private equity fund, which surpassed its $3bn fundraising goal, may invest broadly across health care but the firm already has invested heavily in biopharma. Also, investor Dimension launches with a $350m specialized VC fund and Alto increased its series B to $60m.
You may also be interested in...
Grey Wolf Raises $49m To Bring ‘Tumor Unmasking’ Candidate To Clinic
The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.
Finance Watch: Mega-Rounds Balance Out Influx Of Smaller VC Deals
Private Company Edition: The amount of venture capital investment in biopharma companies has shrunk from quarter to quarter, but the average deal size remained high until the third quarter. Larger rounds from Treeline, Odyssey and Neumora offset a plethora of smaller VC financings early in Q4.
Newly Launched Replay Has Big Plans For Writing and Delivering ‘Big DNA’
With a hub-and-spoke model, Replay has ambitious plans to solve multiple problems in genetic medicine and to disrupt the current AAV gene therapy model.